FindTrial
Sign In

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05561985
Enrollment
Unknown
Registered
2022-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STAT1 Gain-of-Function Disease

Keywords

STAT1 GOF disease

Brief summary

Expanded access use of Itacitinib to treat a single patient with aplastic anemia.

Interventions

DRUGItacitinib

Sponsors

Incyte Corporation
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Contacts

CONTACTIncyte Corporation Call Center (US)
medinfo@incyte.com1.855.463.3463
PRINCIPAL_INVESTIGATORLisa Forbes Satter, MD

Baylor College of Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026